TUESDAY, NOVEMBER 21, 2017

Pfizer gains EU approval for pneumococcal vaccine

The European Commission recently granted an expanded indication for Pfizer, Inc.'s Prevenar 13. Read More »

Serogroup B meningococcal vaccine recommended for at-risk groups

ACIP recommends that people at higher risk receive the serogroup B meningococcal vaccine. Read More »

Top-line results positive for Pfizer's TRUMENBA Phase 2 study

Pfizer, Inc. on Tuesday announced positive top-line results from a phase two study of TRUMENBA, a meningococcal group B vaccine, administered with U.S. Read More »

Volunteers sought to test first oral HIV vaccine

A new oral vaccine to prevent HIV soon may be on the horizon. Read More »

Pfizer obtains herpes vaccine candidate from Redvax

Pfizer recently announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a Swiss biopharmaceutical company. Read More »

Meningococcal Group B vaccine is now FDA-approved and available

In a recent announcement, Pfizer Inc. confirmed that its Meningococcal Group B Vaccine, TRUMENBA® has been approved by the FDA and is now available to US health professionals for active vaccination. Read More »

Pfizer's new meningitis vaccine approved by FDA

The U.S. Read More »

Novartis sells flu vaccine business to CSL Limited for $275M

Drug manufacturer Novartis recently sold its flu vaccine business to CSL Limited for $275 million, pending regulatory approvals. Read More »